Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Bempedoic Acid

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 936Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Esperion (ESPR) Reaches Settlement to Protect Nexletol Patents
    Esperion (ESPR) Reaches Settlement to Protect Nexletol Patents

    02 Jun 2025

    // GURUFOCUS

    https://www.gurufocus.com/news/2901186/esperion-espr-reaches-settlement-to-protect-nexletol-patents-espr-stock-news

    GURUFOCUS
    02 Jun 2025
    Share Share
    MILOS Study Highlights Bempedoic Acid's Potential In Dyslipidemia
    MILOS Study Highlights Bempedoic Acid's Potential In Dyslipidemia

    11 Oct 2024

    // EXPRESSPHARMA

    https://www.expresspharma.in/milos-study-highlights-potential-of-bempedoic-acid-to-advance-dyslipidemia-treatment-globaldata/

    EXPRESSPHARMA
    11 Oct 2024
    Share Share
    MILOS German Cohort Results Show Increase In LDL-C Goal With
    MILOS German Cohort Results Show Increase In LDL-C Goal With

    27 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240926678909/en

    BUSINESSWIRE
    27 Sep 2024
    Share Share
    Bempedoic Acid Cut CVD Risk Across Patient Groups Per CLEAR Outcomes
    Bempedoic Acid Cut CVD Risk Across Patient Groups Per CLEAR Outcomes

    29 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240523300818/en

    BUSINESSWIRE
    29 May 2024
    Share Share
    NILEMDO, NUSTENDI Approved In EU For Cholesterol Lowering
    NILEMDO, NUSTENDI Approved In EU For Cholesterol Lowering

    22 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240514593487/en

    BUSINESSWIRE
    22 May 2024
    Share Share
    FDA Confirms Para IV Patent Litigation for Bempedoic Acid (Nexlizet) Tablets
    FDA Confirms Para IV Patent Litigation for Bempedoic Acid (Nexlizet) Tablets

    26 Apr 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-bempedoic-acid-nexlizet-tablets-6743.pdf

    FDA
    26 Apr 2024
    Share Share